MicroRNAs Repair Heart Cells

Researchers identify microRNAs that keep cardiac cells healthy after heart attack, potentially paving the way for future heart regenerating therapies.

Written bySabrina Richards
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Wikipedia, Heikenwaelder Hugo.Cardiac cells lose most of their capacity for proliferation and regeneration shortly after birth, making it difficult for hearts to recover from damage later in life. But researchers have identified four human microRNAs that can stimulate proliferation of adult rodent cardiac cells in culture and help protect against damage during heart attack in vivo, according to a study published today (December 5) in Nature. If the microRNAs work similarly in human cardiac cells, they may have potential as regenerative therapies after heart damage.

“This is a different approach to repairing damaged cardiac tissue,” said Scot Matkovich, a molecular biologist at Washington University in St. Louis who was not involved in the research. In contrast to stem cell-based approaches, which aim to integrate new cells into the heart, microRNAs (miRNAs) could potentially be a way of “waking up existing cardiomyocytes immediately adjacent to an area of [heart] trauma, still in their native environment, so they can proliferate a little further and fill in the gaps,” Matkovich explained.

Shortly after birth, mammalian heart cells lose most of their capacity to proliferate, which makes it difficult to repair damaged heart tissue, following a heart attack, for example. One approach currently being examined is the use of stem cells, differentiated into cardiomyocytes ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies